Business
Jaguar Health Launches AI-powered Web Portal to Support Patient Access to Mytesi, the Company's FDA-approved Prescription Drug
AI technology is expected to help make it faster and easier for Mytesi® patients to start and stay on the drugSAN FRANCISCO, CA / ACCESSWIRE / May 10, 2023 /
About this update from Jaguar Health, Inc.
[{"type":"text","content":"AI technology is expected to help make it faster and easier for Mytesi® patients to start and stay on the drugSAN FRANCISCO, CA / ACCESSWIRE / May 10, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) (\"Jaguar\" or the \"Company\") today announced that the Company has launched an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi (crofelemer), the Company's FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Access to the portal is available to U.S. healthcare professionals on the Mytesi Healthcare Professionals Site.\"We remain committed to reducing access and reimbursement barriers for Mytesi patients. One key challenge we often hear from patients and their healthcare providers is that payers and insurance companies frequently require prior authorization to approve medication reimbursement, and it can be time-consuming and complicated to provide the needed information,\" said Ian H. Wendt, Jaguar's Chief Commercial Officer. \"Artificial intelligence (AI) technology, like OpenAI's generative AI language models, is an innovative and powerful tool that allows providers to expeditiously communicate their professional judgment by significantly reducing the time and complexity of drafting letters of medical necessity. We believe our user-friendly interface, which employs an OpenAI language model, will help make this otherwise burdensome process easier and faster for healthcare providers to navigate in a compliant way.\"According to a December 2022 American Medical Association (AMA) survey of 1,001 practicing U.S. physicians, an overwhelming majority (88%) of participants describe the burden associated with the prior authorization (PA) process as high or extremely high. The AMA survey also found that 94% of participants reported care delays while waiting for insurers to authorize necessary care, and 80% said issues related to the PA process can lead to patients abandoning their recommended course of treatment.\"The AMA survey found that almost 9 in 10 providers consider the impact of the PA process on patient clinical outcomes as somewhat or significantly negative, indicating that the PA process is currently highly inefficient for the majority of health care providers...